Citadel Advisors
IBB icon

Citadel Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Citadel Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Sell
156,400
-3,100
-2% -$530K ﹤0.01% 1991
2025
Q4 		$26.9M Sell
159,500
-22,400
-12% -$3.64M ﹤0.01% 2028
2025
Q3 		$26.3M Sell
181,900
-251,700
-58% -$34.4M ﹤0.01% 2003
2025
Q2 		$54.9M Buy
433,600
+137,700
+47% +$16.9M 0.01% 1175
2025
Q1 		$37.8M Sell
295,900
-94,000
-24% -$12.7M 0.01% 1385
2024
Q4 		$51.5M Sell
389,900
-157,400
-29% -$22.1M 0.01% 1244
2024
Q3 		$79.7M Buy
547,300
+217,000
+66% +$31.4M 0.02% 856
2024
Q2 		$45.3M Sell
330,300
-158,700
-32% -$21.2M 0.01% 1223
2024
Q1 		$67.1M Sell
489,000
-79,600
-14% -$10.9M 0.01% 990
2023
Q4 		$77.2M Buy
568,600
+217,500
+62% +$26.5M 0.02% 852
2023
Q3 		$42.9M Sell
351,100
-8,500
-2% -$1.08M 0.01% 1192
2023
Q2 		$45.7M Sell
359,600
-200,100
-36% -$26M 0.01% 1122
2023
Q1 		$72.3M Sell
559,700
-186,900
-25% -$24.5M 0.02% 809
2022
Q4 		$98M Buy
746,600
+181,500
+32% +$23.5M 0.02% 665
2022
Q3 		$66.1M Buy
565,100
+177,100
+46% +$22M 0.02% 843
2022
Q2 		$45.6M Buy
388,000
+15,800
+4% +$1.88M 0.01% 1091
2022
Q1 		$48.5M Sell
372,200
-28,200
-7% -$3.67M 0.01% 1144
2021
Q4 		$61.1M Sell
400,400
-73,800
-16% -$11.4M 0.01% 1020
2021
Q3 		$76.7M Sell
474,200
-132,400
-22% -$22.3M 0.02% 821
2021
Q2 		$99.3M Buy
606,600
+155,100
+34% +$23.9M 0.02% 677
2021
Q1 		$68M Sell
451,500
-320,700
-42% -$50.9M 0.02% 803
2020
Q4 		$117M Sell
772,200
-276,200
-26% -$39.5M 0.03% 466
2020
Q3 		$142M Buy
1,048,400
+181,800
+21% +$24.7M 0.04% 300
2020
Q2 		$118M Buy
866,600
+120,700
+16% +$15.4M 0.04% 341
2020
Q1 		$80.4M Sell
745,900
-78,800
-10% -$9.07M 0.04% 426
2019
Q4 		$99.4M Buy
824,700
+226,400
+38% +$25.3M 0.04% 391
2019
Q3 		$59.5M Sell
598,300
-407,700
-41% -$42.7M 0.03% 662
2019
Q2 		$110M Buy
1,006,000
+439,500
+78% +$46.7M 0.05% 364
2019
Q1 		$63.3M Sell
566,500
-229,400
-29% -$25.2M 0.03% 578
2018
Q4 		$76.7M Buy
795,900
+288,000
+57% +$30.6M 0.04% 427
2018
Q3 		$61.9M Sell
507,900
-76,700
-13% -$9.03M 0.03% 636
2018
Q2 		$64.2M Buy
584,600
+49,700
+9% +$5.32M 0.03% 567
2018
Q1 		$57.1M Sell
534,900
-479,600
-47% -$53.2M 0.03% 538
2017
Q4 		$108M Buy
1,014,500
+234,200
+30% +$25M 0.07% 304
2017
Q3 		$86.8M Sell
780,300
-300,600
-28% -$32.1M 0.07% 303
2017
Q2 		$112M Buy
1,080,900
+358,200
+50% +$35.3M 0.09% 197
2017
Q1 		$70.6M Sell
722,700
-236,400
-25% -$22.6M 0.06% 301
2016
Q4 		$84.8M Buy
959,100
+32,700
+4% +$2.98M 0.09% 213
2016
Q3 		$89.4M Buy
+926,400
New +$88.1M 0.09% 194

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's IBB Position: Q1 2026 in Review

Citadel Advisors reduced its iShares Biotechnology ETF (IBB) stake by 80% in Q1 2026, selling an estimated $15.4M and leaving 22,005 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #4852.

Citadel Advisors first reported a position in IBB in Q2 2014 and has held it in 44 quarters since. The position peaked at $85.4M in Q2 2015. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Citadel Advisors held 22,005 shares of iShares Biotechnology ETF worth $3.72M as of Q1 2026.
  • Citadel Advisors sold 89,989 iShares Biotechnology ETF shares in Q1 2026, an estimated $15.4M.
  • iShares Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4852 holding.
  • Citadel Advisors first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 44 quarters since.
  • Citadel Advisors's iShares Biotechnology ETF position peaked at $85.4M in Q2 2015.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.